Get the Stockscreener App
54.87
1.53%
-0.765
Royalty Pharma Plc stock is traded at $54.87, with a volume of 982.42K.
It is down -1.53% in the last 24 hours and up +7.85% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$55.63
Open:
$55.69
24h Volume:
982.42K
Relative Volume:
0.28
Market Cap:
$24.31B
Revenue:
$2.44B
Net Income/Loss:
$1.36B
P/E Ratio:
28.74
EPS:
1.9093
Net Cash Flow:
$574.14M
1W Performance:
-0.35%
1M Performance:
+7.85%
6M Performance:
+43.17%
1Y Performance:
+63.13%
1-Day Range:
$54.74
$56.23
1-Week Range:
$54.35
$56.50
52-Week Range:
$33.59
$56.50
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
54.84 | 24.66B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
437.20 | 113.14B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.75 | 64.60B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
873.59 | 54.97B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.44 | 39.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
143.47 | 31.79B | 742.00K | -1.37B | -1.07B | -7.0731 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | UBS | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Royalty Pharma PLC (NASDAQ:RPRX) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
TD Asset Management Inc Has $9.19 Million Holdings in Royalty Pharma PLC $RPRX - MarketBeat
CenterBook Partners LP Has $2.71 Million Position in Royalty Pharma PLC $RPRX - MarketBeat
Transcript : Royalty Pharma plc Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 04 - marketscreener.com
RPRX: Synthetic royalties and R&D partnerships drive growth, with China and large pharma as key opportunities - TradingView
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance UK
Prudential PLC Decreases Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) director receives 4,545 share unit award - Stock Titan
Royalty Pharma (RPRX) director awarded 4,545 restricted stock units in equity grant - Stock Titan
Director Ted Love receives 4,545 RSUs at Royalty Pharma (RPRX) - Stock Titan
Director at Royalty Pharma (RPRX) receives 4,545 restricted stock units grant - Stock Titan
Royalty Pharma (RPRX) director Carole Ho awarded 4,545 restricted shares - Stock Titan
Royalty Pharma (RPRX) awards 4,545 RSUs to board director - Stock Titan
Royalty Pharma (RPRX) director awarded 4,545 RSUs under 2020 equity plan - Stock Titan
Royalty Pharma (RPRX) director Bonnie Bassler awarded 4,545 RSUs, raising holdings to 78,492 shares - Stock Titan
Royalty Pharma (NASDAQ:RPRX) Hits New 52-Week HighTime to Buy? - MarketBeat
Capital International Inc. CA Acquires 58,030 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Stock Position Increased by Brandywine Global Investment Management LLC - MarketBeat
ROYALTY PHARMA PLC- CL A (RPRX) Stock Chart - ChartMill
Los Angeles Capital Management LLC Purchases 212,294 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Acquired by Capital International Ltd. CA - MarketBeat
Capital International Sarl Purchases 166,334 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Purchased by Capital International Investors - MarketBeat
Capital Group Investment Management PTE. LTD. Has $2.53 Million Stake in Royalty Pharma PLC $RPRX - MarketBeat
Cash from operating activities of Royalty Pharma Plc Class A – XETR:RPD - TradingView
Operating expenses (excl. COGS) of Royalty Pharma Plc Class A – XETR:RPD - TradingView
Non-controlling/minority interest of Royalty Pharma Plc Class A – XETR:RPD - TradingView
(RPRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Norges Bank Invests $131.92 Million in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
Royalty Pharma (RPRX) shareholders back directors, pay and share issuance powers at 2026 AGM - Stock Titan
Nomura Asset Management Co. Ltd. Boosts Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Purchased by BNP Paribas Financial Markets - MarketBeat
Royalty Pharma (RPRX) Q1 2026 Earnings Transcript - AOL.com
Hillsdale Investment Management Inc. Acquires 23,700 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Geode Capital Management LLC Acquires 102,430 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc (RPRX) Stock Analysis: Evaluating Its 6.26% Potential Upside and Strong Buy Ratings - DirectorsTalk Interviews
Royalty Pharma Secures New $1.8 Billion Credit Facility - The Globe and Mail
Royalty Pharma signs $500M co-development agreement with J&J - MSN
Royalty Pharma stock hits 52-week high at 54.82 USD By Investing.com - Investing.com Nigeria
Royalty Pharma stock hits 52-week high at 54.82 USD - Investing.com
United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Purchases Shares of 234,551 Royalty Pharma PLC $RPRX - MarketBeat
Legal & General Group Plc Has $119.32 Million Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma EVP & CFO Coyne sells $3.48 million in shares - Investing.com India
Royalty Pharma EVP & CFO Coyne sells $3.48 million in shares By Investing.com - Investing.com South Africa
Royalty Pharma (RPRX) CFO-linked entity sells 64,399 shares under 10b5-1 plan - Stock Titan
Royalty Pharma plc Enters into Revolving Credit Agreement - marketscreener.com
Royalty Pharma (NASDAQ: RPRX) renews $1.8B unsecured revolver to 2031 - Stock Titan
Royalty Pharma Plc Hits New 52-Week High of $54.74 - Markets Mojo
Royalty Pharma Plc Hits New 52-Week High at $54.63 - Markets Mojo
How Investors May Respond To Royalty Pharma (RPRX) Strong Q1 Royalties And Expanding Biotech Partnerships - Sahm
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):